Insook Kim1, Sharat Srinivasula2, Paula DeGrange3, Brad Long3, Hyukjin Jang2, Jorge A Carrasquillo4,5, H Clifford Lane6, Michele Di Mascio7. 1. AIDS Imaging Research Section, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA. 2. AIDS Imaging Research Section, Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA. 3. AIDS Imaging Research Section, Integrated Research Facility, NIAID, NIH, Frederick, MD, 21702, USA. 4. Molecular Imaging and Therapy Service, Radiology Department, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 5. Molecular Imaging Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, 20892, USA. 6. Laboratory of Immunoregulation, Division of Intramural Research, NIAID, NIH, Bethesda, MD, 20892, USA. 7. AIDS Imaging Research Section, Division of Clinical Research, NIAID, NIH, Bethesda, MD, 20892, USA. mdimascio@niaid.nih.gov.
Abstract
PURPOSE: Previous SPECT and PET semi-quantitative in vivo imaging studies in monkeys have demonstrated specific uptake of radiolabeled rhesus recombinant anti-CD4 monoclonal antibody fragment CD4R1-F(ab΄)2 in the spleen and clusters of lymph nodes (LNs) but yielded conflicting results of imaging the gut CD4 + T-cell pool. Here, using PET dynamic imaging with kinetic analysis, we performed a fully quantitative CD4 imaging in rhesus macaques. METHODS: The biodistributions of [89Zr]Zr-CD4R1-F(ab΄)2 and/or of [89Zr]Zr-ibalizumab were performed with static PET scans up to 144 h (6 days) post-injection in 18 rhesus macaques with peripheral blood CD4 + T cells/μl ranging from ~ 20 to 2400. Fully quantitative analysis with a 4-h dynamic scan, arterial sampling, metabolite evaluation, and model fitting was performed in three immunocompetent monkeys to estimate the binding potential of CD4 receptors in the LNs, spleen, and gut. RESULTS: The biodistributions of [89Zr]Zr-CD4R1-F(ab΄)2 and [89Zr]Zr-ibalizumab were similar in lymphoid tissues with a clear delineation of the CD4 pool in the LNs and spleen and a significant difference in lymphoid tissue uptake between immunocompetent and immunocompromised macaques. Consistent with our previous SPECT imaging of [99mTc]Tc-CD4R1-F(ab΄)2, the [89Zr]Zr-CD4R1-F(ab΄)2 and [89Zr]Zr-Ibalizumab uptakes in the gut were low and not different between uninfected and SIV-infected CD4-depleted monkeys. Ex vivo studies of large and small intestines confirmed the in vivo images. CONCLUSION: The majority of specific binding to CD4 + tissue was localized to LNs and spleen with minimal uptake in the gut. Binding potential derived from fully quantitative studies revealed that the contribution of the gut is lower than the spleen's contribution to the total body CD4 pool.
PURPOSE: Previous SPECT and PET semi-quantitative in vivo imaging studies in monkeys have demonstrated specific uptake of radiolabeled rhesus recombinant anti-CD4 monoclonal antibody fragment CD4R1-F(ab΄)2 in the spleen and clusters of lymph nodes (LNs) but yielded conflicting results of imaging the gut CD4 + T-cell pool. Here, using PET dynamic imaging with kinetic analysis, we performed a fully quantitative CD4 imaging in rhesus macaques. METHODS: The biodistributions of [89Zr]Zr-CD4R1-F(ab΄)2 and/or of [89Zr]Zr-ibalizumab were performed with static PET scans up to 144 h (6 days) post-injection in 18 rhesus macaques with peripheral blood CD4 + T cells/μl ranging from ~ 20 to 2400. Fully quantitative analysis with a 4-h dynamic scan, arterial sampling, metabolite evaluation, and model fitting was performed in three immunocompetent monkeys to estimate the binding potential of CD4 receptors in the LNs, spleen, and gut. RESULTS: The biodistributions of [89Zr]Zr-CD4R1-F(ab΄)2 and [89Zr]Zr-ibalizumab were similar in lymphoid tissues with a clear delineation of the CD4 pool in the LNs and spleen and a significant difference in lymphoid tissue uptake between immunocompetent and immunocompromised macaques. Consistent with our previous SPECT imaging of [99mTc]Tc-CD4R1-F(ab΄)2, the [89Zr]Zr-CD4R1-F(ab΄)2 and [89Zr]Zr-Ibalizumab uptakes in the gut were low and not different between uninfected and SIV-infected CD4-depleted monkeys. Ex vivo studies of large and small intestines confirmed the in vivo images. CONCLUSION: The majority of specific binding to CD4 + tissue was localized to LNs and spleen with minimal uptake in the gut. Binding potential derived from fully quantitative studies revealed that the contribution of the gut is lower than the spleen's contribution to the total body CD4 pool.
Authors: Robert E Donahue; Sharat Srinivasula; Naoya Uchida; Insook Kim; Alexis St Claire; Gorka Duralde; Paula DeGrange; Marisa St Claire; Richard C Reba; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Chang H Paik; H Clifford Lane; John F Tisdale; Michele Di Mascio Journal: Blood Date: 2015-10-22 Impact factor: 22.113
Authors: Siddappa N Byrareddy; James Arthos; Claudia Cicala; Francois Villinger; Kristina T Ortiz; Dawn Little; Neil Sidell; Maureen A Kane; Jianshi Yu; Jace W Jones; Philip J Santangelo; Chiara Zurla; Lyle R McKinnon; Kelly B Arnold; Caroline E Woody; Lutz Walter; Christian Roos; Angela Noll; Donald Van Ryk; Katija Jelicic; Raffaello Cimbro; Sanjeev Gumber; Michelle D Reid; Volkan Adsay; Praveen K Amancha; Ann E Mayne; Tristram G Parslow; Anthony S Fauci; Aftab A Ansari Journal: Science Date: 2016-10-14 Impact factor: 47.728
Authors: Michele Di Mascio; Chang H Paik; Jorge A Carrasquillo; Jin-Soo Maeng; Beom-Su Jang; In Soo Shin; Sharat Srinivasula; Russ Byrum; Achilles Neria; William Kopp; Marta Catalfamo; Yoshiaki Nishimura; Keith Reimann; Malcolm Martin; H Clifford Lane Journal: Blood Date: 2009-05-05 Impact factor: 22.113
Authors: Saurabh Mehandru; Michael A Poles; Klara Tenner-Racz; Amir Horowitz; Arlene Hurley; Christine Hogan; Daniel Boden; Paul Racz; Martin Markowitz Journal: J Exp Med Date: 2004-09-13 Impact factor: 14.307
Authors: Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek Journal: J Exp Med Date: 2004-09-13 Impact factor: 14.307
Authors: P J Santangelo; C Cicala; S N Byrareddy; K T Ortiz; D Little; K E Lindsay; S Gumber; J J Hong; K Jelicic; K A Rogers; C Zurla; F Villinger; A A Ansari; A S Fauci; J Arthos Journal: Mucosal Immunol Date: 2017-12-20 Impact factor: 7.313